TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33916810

Group type: EXPERIMENTAL
Intervention: 10-item questionnaire
Number of subjects: 839
Study: 35507446

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) continuation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg) withdrawal
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MCID cut-offs for I-RODS and MRC-SS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined MCIDs
Number of subjects: 60
Study: 32593791

Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 32631102

Group type: EXPERIMENTAL
Intervention: Intervention to promote handwashing with soap
Number of subjects: 14
Study: 34109590

Group type: EXPERIMENTAL
Intervention: Rehabilitation training on the basis of routine drug therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine medication
Number of subjects: 100
Study: 36191597

Group type: EXPERIMENTAL
Intervention: Polycaprolactone injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sodium hyaluronate gel injection
Number of subjects: 80
Study: 33516674

Group type: EXPERIMENTAL
Intervention: Cognition-enhancing medications
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Opioid medications
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 1135
Study: 33131315

Group type: EXPERIMENTAL
Intervention: High office blood pressure variability (OBPV) - highest tertile
Number of subjects: 16475
Study: 35803619

Group type: EXPERIMENTAL
Intervention: Biophilic VR
Number of subjects: 600

Group type: COMPARATOR
Intervention: Sham VR
Number of subjects: 600
Study: 34186056

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 36031273

Group type: EXPERIMENTAL
Intervention: Non-punitive performance feedback via weekly text messages about driving score and rank
Number of subjects: 1393
Study: 32074474

Group type: EXPERIMENTAL
Intervention: Secure electronic messaging
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Clinician responses based on patients' demographics
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Message content analysis
Number of subjects: 73
Study: 36715629

Group type: EXPERIMENTAL
Intervention: Ostomy baseplate with skin-protection technology
Number of subjects: 79

Group type: COMPARATOR
Intervention: Comparator product (SenSura® Mio)
Number of subjects: 79
Study: 32031757

Group type: EXPERIMENTAL
Intervention: Treatment for conversion disorder/functional neurological disorder (CD/FND)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Comorbid depression treatment
Number of subjects: 64
Study: 36253729

Group type: EXPERIMENTAL
Intervention: Standard volume ESPB with 20 ml 0.25% bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High volume ESPB with 40 ml 0.125% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: GA only group (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High volume ESPB
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standard volume ESPB
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both ESPB groups
Number of subjects: 60
Study: 32513562

Group type: EXPERIMENTAL
Intervention: Partner-delivered relaxation massage
Number of subjects: 27

Group type: COMPARATOR
Intervention: Self-directed stress management
Number of subjects: 27
Study: 32907752

Group type: COMPARATOR
Intervention: G0 (0 days pH cycling)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: G14 (14 days pH cycling)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: G21 (21 days pH cycling)
Number of subjects: 96
Study: 35410367

Group type: EXPERIMENTAL
Intervention: Orthoptic therapy (at least 2 months) including anti-suppression, vergence, and accommodation training
Number of subjects: 136

Group type: COMPARATOR
Intervention: Blank control (only refractive correction)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Orthoptic therapy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 136
Study: 33606764

Group type: EXPERIMENTAL
Intervention: Desflurane-based inhalational anesthesia
Number of subjects: 68

Group type: COMPARATOR
Intervention: Propofol-based TIVA
Number of subjects: 68
Study: 32407239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined histamine H1/H2-receptor antagonists (Blockade)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Blockade
Number of subjects: 16
Study: 33959852

Group type: EXPERIMENTAL
Intervention: Active oral orthotic (occlusal splint)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham orthotic
Number of subjects: 13
Study: 34941917

Group type: COMPARATOR
Intervention: Control facial expression manipulation after self-focus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smiling facial expression manipulation after self-focus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facial expressions after other-focus manipulation
Number of subjects: 0
Study: 35877927

Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) supplementation (n = 213)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo (n = 212)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) supplementation
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study: 33541117

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 1471

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 1471

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1471
Study: 32758379

Group type: EXPERIMENTAL
Intervention: Knee Arthroscopy after TKA (TKA + KA group)
Number of subjects: 192

Group type: COMPARATOR
Intervention: No Knee Arthroscopy after TKA (TKA - KA group)
Number of subjects: 192
Study: 35881051

Group type: EXPERIMENTAL
Intervention: Belumosudil (200 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Belumosudil (1000 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 34028830

Group type: EXPERIMENTAL
Intervention: NAFLD (non-alcoholic fatty liver disease) defined by a fatty liver index score of 60 or more in people without excessive alcohol intake or viral hepatitis.
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Metabolic risk factors associated with NAFLD
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Serum alanine aminotransferase levels
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Liver stiffness measurements
Number of subjects: 705
Study: 32391862

Group type: EXPERIMENTAL
Intervention: Multifaceted antimicrobial stewardship intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 25
Study: 35364385

Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 34131048

Group type: EXPERIMENTAL
Intervention: Liraglutide plus Metformin (LIRA+MET)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Glargine followed by Metformin (G-MET)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study: 32132348

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (BM‐MNC) implantation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Internal controls
Number of subjects: 27

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 27
Study: 36096832

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting MACE
Number of subjects: 1206
Study: 33743659

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA) injection
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 41

Group type: COMPARATOR
Intervention: Condom use
Number of subjects: 41

Group type: COMPARATOR
Intervention: Contraception and condom use
Number of subjects: 41
Study: 34132512

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 14
Study: 34134029

Group type: COMPARATOR
Intervention: High stress level in FGIDs population
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stress as an independent predictor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stressor 'changes'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stressor 'frustration'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stressor 'physiological reaction'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple gastrointestinal symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediation effect of stress
Number of subjects: 0
Study: 34541744

Group type: EXPERIMENTAL
Intervention: 7-octave pure tone sound therapy based on tinnitus characteristics
Number of subjects: 92

Group type: COMPARATOR
Intervention: 9 one-third octave pure tone sound therapy based on tinnitus characteristics
Number of subjects: 92
Study: 36482335

Group type: EXPERIMENTAL
Intervention: Diagnostic CT enabled planning (Arm 2)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional CT simulation (Arm 1)
Number of subjects: 33
Study: 32244296

Group type: COMPARATOR
Intervention: Enzyme Replacement Therapy (ERT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substrate Reduction Therapy (SRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated (UT)
Number of subjects: 0
Study: 33709889

Group type: EXPERIMENTAL
Intervention: Matching-Adjusted Indirect Comparisons for hematological and oncological treatments
Number of subjects: 13
Study: 32730561

Group type: EXPERIMENTAL
Intervention: Nonoperative management with antibiotics (n=370)
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Urgent laparoscopic appendectomy (n=698)
Number of subjects: 1068
Study: 35393360

Group type: EXPERIMENTAL
Intervention: 100 mg indobufen two times daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: 100 mg aspirin once daily
Number of subjects: 200
Study: 34007245

Group type: EXPERIMENTAL
Intervention: Spiritual wellbeing assessment using the Functional Assessment of Chronic Illness Therapy‐Spiritual Well‐Being Scale‐12
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Demographic and clinical factors (place of residence, marital status, educational level, comorbidities)
Number of subjects: 367
Study: 32915892

Group type: EXPERIMENTAL
Intervention: Nebivolol (5mg for 2 weeks/10mg for 10 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Diltiazem (90mg for 2 weeks/180mg for 10 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Low-dose Combination (2.5mg + 45mg for 2 weeks/5mg + 90mg for 10 weeks)
Number of subjects: 51
Study: 35753968

Group type: EXPERIMENTAL
Intervention: Trunk stabilising exercises performed three times per week for 4 weeks in addition to cardiac rehabilitation.
Number of subjects: 36
Study: 34776169

Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Epley maneuver and Cawthorne-Cooksey vestibular exercises
Number of subjects: 36
Study: 36137957

Group type: EXPERIMENTAL
Intervention: iTBS combined with cognitive training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: tDCS combined with cognitive training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive training alone
Number of subjects: 60
Study: 32205034

Group type: EXPERIMENTAL
Intervention: Wearable cardioverter-defibrillator (WCD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34968130

Group type: EXPERIMENTAL
Intervention: Dyadic planning
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Collaborative planning
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Individual planning
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control condition (physical activity, sedentary behavior, and nutrition education)
Number of subjects: 320
Study: 33724890

Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia (H)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia (H) + Virtual Reality distraction (VR)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Virtual Reality distraction (VR)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Hypnotic analgesia (H) alone
Number of subjects: 205
Study: 32151528

Group type: EXPERIMENTAL
Intervention: Lens A (senofilcon A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lens B (balafilcon A)
Number of subjects: 30
Study: 36101515

Group type: EXPERIMENTAL
Intervention: Micellar curcumin (105 mg day-1) for 7 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Native curcumin (105 mg day-1) for 7 days
Number of subjects: 15
Study: 33225791

Group type: EXPERIMENTAL
Intervention: Placental weight
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Placental length
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Maximum cord diameter
Number of subjects: 411
Study: 36209239

Group type: EXPERIMENTAL
Intervention: Apalutamide in addition to ongoing androgen deprivation therapy (ADT)
Number of subjects: 806

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 806
Study: 33662954

Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis (MS)
Number of subjects: 4461
Study: 32593255

Group type: EXPERIMENTAL
Intervention: Plasma enriched with platelets combined with traditional treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional treatment alone
Number of subjects: 80
Study: 35871950

Group type: EXPERIMENTAL
Intervention: OPF-105 (150 g dextrose, 60 g amino acids, 40 g fat, 1240 kcal per 2200 mL)
Number of subjects: 35

Group type: COMPARATOR
Intervention: BFI (150 g dextrose, 60 g amino acids, 840 kcal per 2000 mL)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: OPF-105 (multiple doses for 3 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: BFI (multiple doses for 3 days)
Number of subjects: 35
Study: 34435993

Group type: EXPERIMENTAL
Intervention: Early exercise intervention (Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Later exercise intervention (Group 2)
Number of subjects: 40
Study: 33123091

Group type: EXPERIMENTAL
Intervention: 200 μg oral iodine daily until delivery
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study: 35506470

Group type: EXPERIMENTAL
Intervention: WRAP®
Number of subjects: 182

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 182
Study: 34515669

Group type: EXPERIMENTAL
Intervention: Audit and Feedback report
Number of subjects: 833

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 833
Study: 35666855

Group type: EXPERIMENTAL
Intervention: Study formula (SF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial formula (CF)
Number of subjects: 0
Study: 32680894

Group type: EXPERIMENTAL
Intervention: Domus intervention (specialised palliative home care with psychological intervention)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Hospice SPT (specialised palliative home teams)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Domus intervention
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 322
Study: 35149656

Group type: EXPERIMENTAL
Intervention: Nurse-led telephonic palliative care
Number of subjects: 4

Group type: COMPARATOR
Intervention: Outpatient palliative care
Number of subjects: 4
Study: 33683736

Group type: EXPERIMENTAL
Intervention: Computer-aided detection system (CADS) based on convolutional neural network (CNN)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: CADS
Number of subjects: 65
Study: 32413774

Group type: EXPERIMENTAL
Intervention: G‐Lok™ with G‐Lok‐XL™ (fixed loop)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ProCinch™ with G‐Lok‐XL™ (adjustable loop)
Number of subjects: 27

Group type: COMPARATOR
Intervention: G‐Lok™ (control with socket tunnel)
Number of subjects: 27
Study: 35861301

Group type: EXPERIMENTAL
Intervention: Low-dose calcineurin inhibitor (CNI) combined with sirolimus (SRL) after four weeks of standard regimen.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (CNI + MPA + glucocorticoid) maintained after four weeks.
Number of subjects: 0
Study: 33964852

Group type: EXPERIMENTAL
Intervention: Daily consumption of 3 whole Gala apples (∼200 g edible parts)/d for 6 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (avoided apples)
Number of subjects: 46
Study: 32601731

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35837181

Group type: EXPERIMENTAL
Intervention: Acupuncture at bilateral Hegu (LI 4) and Neiguan (PC 6) points
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 54
Study: 33187518

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) intake (140 mL, 12.8 mmol NO3‐)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) intake
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo intake
Number of subjects: 12
Study: 33367965

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32622603

Group type: EXPERIMENTAL
Intervention: Heat-treated canola meal (CM) at 110°C for 10 min
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Glycerol inclusion (0 or 5% on a dry matter basis)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (CM without heat treatment)
Number of subjects: 28
Study: 37034559

Group type: EXPERIMENTAL
Intervention: liraglutide 3.0 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 32750730

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 32430375

Group type: EXPERIMENTAL
Intervention: Having a primary care physician (PCP)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Native English speaking
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Higher Charlson comorbidity index score
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Identifying as women
Number of subjects: 400

Group type: COMPARATOR
Intervention: Socioeconomic status score, quantity of contact information recorded at recruitment, and insurance status
Number of subjects: 400
Study: 34688521

Group type: EXPERIMENTAL
Intervention: Beverage messages (sugary drink discouragement, water encouragement, or combined)
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Beverage messages
Number of subjects: 2164

Group type: COMPARATOR
Intervention: Control messages (school readiness)
Number of subjects: 2164
Study: 32552433

Group type: COMPARATOR
Intervention: Pdimax50% (50% of maximal inspiratory mouth and transdiaphragmatic pressure)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pdimax70% (70% of maximal inspiratory mouth and transdiaphragmatic pressure)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no resistance)
Number of subjects: 8
Study: 36418131

Group type: EXPERIMENTAL
Intervention: Clinically assisted hydration (CAH) including parenteral fluids (dextrose saline 4% dextrose, 0.18% sodium chloride)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Usual end-of-life care (continuance of drinking, mouth care)
Number of subjects: 1600
Study: 33820788

Group type: EXPERIMENTAL
Intervention: Aerobic exercise at an intensity of 4.5 METs for 150 min per week for 16 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Increased intensity group training at 6.0 METs for 150 min per week for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Maintained intensity group training at 4.5 METs for 150 min per week for 12 weeks
Number of subjects: 60
Study: 32766705

Group type: EXPERIMENTAL
Intervention: Telemedicine group (TG) with access to a CCDSS platform
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (CG) with treatment as usual (TAU)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 98
Study: 33389660

Group type: EXPERIMENTAL
Intervention: Digital storytelling (DS) intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Information control (IC)
Number of subjects: 40
Study: 33740911

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 70
Study: 32362510

Group type: EXPERIMENTAL
Intervention: Intervention (sexual violence education training for health center staff)
Number of subjects: 2291

Group type: COMPARATOR
Intervention: Control (information about drinking responsibly)
Number of subjects: 2291
Study: 35245661

Group type: EXPERIMENTAL
Intervention: 300 mg/day allopurinol
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 35028116

Group type: EXPERIMENTAL
Intervention: Diabetes health education care model
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 90
Study: 34139038

Group type: EXPERIMENTAL
Intervention: Vibegron 50 mg (V50)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibegron 100 mg (V100)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vibegron (V50/100)
Number of subjects: 0
Study: 32039871

Group type: EXPERIMENTAL
Intervention: Combined scalp acupuncture and cognitive training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham scalp acupuncture and cognitive training
Number of subjects: 70
Study: 33576579

Group type: EXPERIMENTAL
Intervention: New perioperative practice model with one named anaesthesia nurse
Number of subjects: 453

Group type: COMPARATOR
Intervention: Standard perioperative care with various nurses
Number of subjects: 453
Study: 32472663

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acustimulation (TEA)
Number of subjects: 108